Vol 5, Supplement 3 (September 29, 2016): Translational Cancer Research

Editorial

Tailor the adjuvant hormonal manipulation for premenopausal breast cancer patients

Tom Wei-Wu Chen, Ching-Hung Lin, Yen-Shen Lu

PDF Pages: S380-S384 Full Text (3814) COI Form Open Access

Adjuvant chemotherapy for locally advanced bladder cancer—a step closer to ending the ongoing controversy

Sanjay Patel, Michael Cookson

PDF Pages: S385-S386 Full Text (2811) COI Form Open Access

More is not always better: clinical genetics of familial breast cancer in the era of massively enhanced sequencing capacities

Martin Schreiber

PDF Pages: S387-S391 Full Text (3833) COI Form Open Access

Akt1/Akt2 inhibition and development of hepatocellular carcinoma

Rosina Maria Critelli, Filippo Schepis, Erica Villa

PDF Pages: S392-S394 Full Text (4670) COI Form Open Access

Mutational and transcriptome based sub-classification of pancreatic cancer: are we there yet?

Vrishketan Sethi, Bharti Garg, Ashok Saluja, Vikas Dudeja

PDF Pages: S395-S399 Full Text (3191) Open Access

A lovely leap toward the development of breast cancer therapy with long non-coding RNAs

Tomoshige Kino, Alexandra K. Marr

PDF Pages: S400-S404 Full Text (4056) COI Form Open Access

Multimodality imaging for early assessment of head and neck patients during induction chemotherapy: a reliable future option?

Filippo Alongi, Rosario Mazzola

PDF Pages: S405-S407 Full Text (3060) COI Form Open Access

Immune checkpoint blockade (ICB) for first line treatment in non-small-cell lung cancer (NSCLC)

Rafael Rosell, Niki Karachaliou, Aaron Sosa, Santiago Viteri

PDF Pages: S408-S410 Full Text (3838) COI Form Open Access

Post radiofrequency ablation assessment of colorectal cancer liver metastases—does post ablation biopsy really matter?

Hanping Wu, Agata A. Exner, Sidhartha Tavri

PDF Pages: S411-S414 Full Text (4292) COI Form Open Access

The CROSS road in neoadjuvant therapy for esophageal cancer: long-term results of CROSS trial

Ian Wong, Simon Law

PDF Pages: S415-S419 Full Text (30787) COI Form Open Access

Personalized molecular targeted therapy for hepatocellular carcinoma in the era of genome sequencing

Massimiliano Cadamuro, Mario Strazzabosco, Luca Fabris

PDF Pages: S420-S424 Full Text (5148) COI Form Open Access

Afatinib and gefitinib: a direct comparison

Cesare Gridelli, Tania Losanno

PDF Pages: S425-S427 Full Text (5473) Open Access

Another important step towards understanding tumor immune evasion—novel mechanisms of PD-L1 overexpression

Young Kwang Chae, Ayush Arya, Jonathan Anker, Francis Giles

PDF Pages: S428-S432 Full Text (3980) COI Form Open Access

Balancing redox stress: anchorage-independent growth requires reductive carboxylation

Clint.A Stalnecker, Ahmad.A Cluntun, Richard.A Cerione

PDF Pages: S433-S437 Full Text (6657) COI Form Open Access

Chemo-radiotherapy free conditioning regimen: immunotoxin at its magical best

Ranjit Kumar Sahoo, Lalit Kumar

PDF Pages: S438-S443 Full Text (4438) COI Form Open Access

Novel toxicology challenges in the era of chimeric antigen receptor T-cells therapies

Kentaro Minagawa, Antonio Di Stasi

PDF Pages: S444-S449 Full Text (4605) COI Form Open Access

Should we incorporate ablative radiotherapy in standard treatment of advanced intrahepatic cholangiocarcinoma?

Giovanni Brandi, Andrea Palloni, Alessio Giuseppe Morganti

PDF Pages: S450-S453 Full Text (3160) COI Form Open Access

Durvalumab (MEDI4736; anti-PD-L1 inhibitor): to shed light on the treatment of advanced urothelial bladder cancer patients refractory to systemic chemotherapy

Minyong Kang, Ja Hyeon Ku

PDF Pages: S454-S457 Full Text (3674) COI Form Open Access

Expanding therapies for crizotinib refractory ALK-rearranged nonsmall cell lung cancer

Tristan A. Barnes, Natasha B. Leighl

PDF Pages: S458-S461 Full Text (3445) Open Access

Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that?

Roberto Ferrara, Mario Caccese, Federica Cuppone, Emilio Bria, Giampaolo Tortora, Sara Pilotto

PDF Pages: S462-S466 Full Text (4975) COI Form Open Access

BIRC3 as a yet underestimated prognostic marker of malignancies?

Thomas Liehr

PDF Pages: S467-S469 Full Text (5352) COI Form Open Access

Atezolizumab in lung cancer—appreciating the differences

Stephen V. Liu, Giuseppe Giaccone

PDF Pages: S470-S473 Full Text (3693) Open Access

Pushing the limits in pancreatic cancer therapy

Dionysios Koliogiannis, Jens Werner, Werner Hartwig

PDF Pages: S474-S476 Full Text (3493) COI Form Open Access

Perspective

Program death-1 (PD-1) receptor pathway inhibition in cancer medicine: a perspective on clinical efficacy and associated toxicities

Luis H. Camacho

PDF Pages: S477-S484 Full Text (5185) Open Access

The STAMPEDE trial: paradigm-changing data through innovative trial design

Bradley C. Carthon, Emmanuel S. Antonarakis

PDF Pages: S485-S490 Full Text (10883) Open Access

Pharmacological management update: clinical significance of anamorelin clinical trials for the treatment of cancer cachexia in advanced cancer patients

Terence Rong De Ng, Eduardo Bruera, Sriram Yennurajalingam

PDF Pages: S491-S496 Full Text (3972) COI Form Open Access

Activation of calcineurin in cancer: many paths, one hub

Miranda Brun, Roseline Godbout

PDF Pages: S497-S506 Full Text (11626) COI Form Open Access

Feed your gut with caution!

Vishal Singh, Beng San Yeoh, Matam Vijay-Kumar

PDF Pages: S507-S513 Full Text (9778) COI Form Open Access

Regulation of chemo-sensitivity in ovarian cancer via a stroma dependent glutathione pathway

Derek B. Oien, Jeremy Chien, Nikki Cheng

PDF Pages: S514-S519 Full Text (6625) COI Form Open Access

Intracranial efficacy of crizotinib versus chemotherapy in PROFILE 1014: shining a light on central nervous system endpoints in clinical trials

Terry L. Ng, D. Ross Camidge

PDF Pages: S520-S525 Full Text (4639) COI Form Open Access

Research Highlight

Butyrate consumption of differentiated colonocytes in the upper crypt promotes homeostatic proliferation of stem and progenitor cells near the crypt base

Scott J. Bultman

PDF Pages: S526-S528 Full Text (5814) COI Form Open Access

Commentary

Directing abiraterone metabolism: balancing the scales between clinical relevance and experimental observation

Jon K. Obst, Marianne D. Sadar

PDF Pages: S529-S531 Full Text (4798) COI Form Open Access

Immune checkpoint inhibitors in non-small cell lung cancer: is simultaneous blockade better?

Jennifer T. Eubanks, Suresh S. Ramalingam

PDF Pages: S532-S535 Full Text (3259) Open Access

Colonic crypts are natural gatekeepers of microbial metabolites to protect stem cells

Praveen Kumar Vemula, Venkatakrishna Rao Jala

PDF Pages: S536-S539 Full Text (6501) COI Form Open Access

Theranostic siRNA conjugated nanoparticles: the possible central role of superparagmetic iron oxide nanoparticles as a new transfer vehicle system for therapy and diagnostic in human cancer therapy

Eckhard Klieser, Daniel Neureiter

PDF Pages: S540-S543 Full Text (3372) COI Form Open Access

Mastectomy in precision oncology era: myth or reality?

Gianluca Franceschini, Armando Orlandi, Alejandro Martin Sanchez, Maria Alessandra Calegari, Riccardo Masetti

PDF Pages: S544-S545 Full Text (2712) COI Form Open Access

Some aspects of mutant p53 in ovarian cancer biology

Sabine Heublein

PDF Pages: S546-S547 Full Text (2764) COI Form Open Access

Commentary on a randomized controlled trial of vagus nerve- preserving distal gastrectomy in early gastric cancer

Mikita Inokuchi, Sho Otsuki, Tatsuyuki Kawano, Kazuyuki Kojima

PDF Pages: S548-S550 Full Text (3183) COI Form Open Access

Drivers of neuroendocrine prostate cancer

Filipe Pinto, Rui Manuel Reis

PDF Pages: S551-S553 Full Text (4386) COI Form Open Access

Crizotinib for ALK rearrangement-positive non-small cell lung cancer patients with central nervous system metastasis

Masayuki Takeda, Kazuhiko Nakagawa

PDF Pages: S554-S556 Full Text (3530) Open Access

Helicobacter pylori vacuolating cytotoxin and gastric cancer risk: reconsidered

Muhammad Miftahussurur, Yoshio Yamaoka, David Y. Graham

PDF Pages: S557-S560 Full Text (5771) Open Access

Extracellular vesicles in cancer: current status and challenges

Nami O. Yamada

PDF Pages: S561-S563 Full Text (3771) COI Form Open Access

Long non-coding RNAs: new opportunities and old challenges in cancer therapy

Gwyn T. Williams, Mark R. Pickard

PDF Pages: S564-S566 Full Text (3999) COI Form Open Access

GAS5 oligonucleotides as therapeutic agents in breast cancer

Merdan Fayda, Ugur Gezer

PDF Pages: S567-S568 Full Text (3125) COI Form Open Access

Estrogen receptor and human epidermal growth factor receptor-2 quantification and efficacy to trastuzumab

Paolo Nuciforo

PDF Pages: S569-S571 Full Text (3219) COI Form Open Access

ETV1 combines tumor cell plasticity with constitution of a pro-tumorigenic stroma in pancreatic cancer

Robert Götze, Volker Ellenrieder

PDF Pages: S572-S573 Full Text (2742) COI Form Open Access

Video-assisted thoracoscopic surgery or open thoracotomy approach for surgery for non-small cell lung cancer—no definitive answer, yet

Marcin Zielinski

PDF Pages: S574-S575 Full Text (2383) COI Form Open Access

Predicting the response to anti-PD1 therapy in metastatic melanoma

Lucie Heinzerling, Michael Constantin Kirchberger, Lisa Walter, Gerold Schuler

PDF Pages: S576-S579 Full Text (7151) Open Access

Oncogenic combined calcineurin-nuclear factor of activated T cells and toll-like receptor signals in colon

Masashi Muramatsu, Takashi Minami

PDF Pages: S580-S583 Full Text (3603) COI Form Open Access

The role of the liquid biopsy as a clinical tool for early prediction in prostate cancer

Michael J. Donovan

PDF Pages: S584-S586 Full Text (2777) Open Access

Cyclin dependent kinase 5—a novel target to enhance the antitumor immune response

Johanna Liebl

PDF Pages: S587-S589 Full Text (4182) COI Form Open Access

Bendamustine and rituximab for the treatment of relapsed indolent and mantle cell lymphoma: when timing of a study matters

Lorenzo Falchi, Rita Morales, Marco Ruella

PDF Pages: S590-S594 Full Text (6927) COI Form Open Access

Signals derived from the commensal microbiota to promote intestinal tumor development

Swapna Chaudhuri

PDF Pages: S595-S597 Full Text (3310) COI Form Open Access

Correspondence

The driving role of cancer-testis genes: a new perspective for cancer researches

Cheng Wang, Hongbing Shen, Zhibin Hu

PDF Pages: S598-S600 Full Text (2885) COI Form Open Access

Apatinib: get better application in gastric cancer and other cancers

Shukui Qin, Jin Li

PDF Pages: S601-S603 Full Text (4514) COI Form Open Access

Understanding intra-tumor heterogeneity and tumor evolution to facilitate hepatocellular carcinoma therapy

Ruidong Xue, Ruoyan Li, Ning Zhang, Fan Bai

PDF Pages: S604-S605 Full Text (2933) COI Form Open Access

Emerging roles of prolactin-mediated BRCA1 function

Kuan-Hui.Ethan Chen, Ameae.M Walker

PDF Pages: S606-S607 Full Text (2961) COI Form Open Access

Biomarkers France: a first and distinctive step in assessing the impact of non-small cell lung cancer (NSCLC) patients routine molecular profiling

Fabrice Barlesi, Jean-Charles Soria, Dominique Maraninchi, Norbert Ifrah, Denis Moro-Sibilot

PDF Pages: S608-S609 Full Text (3057) COI Form Open Access

Canine factor VII deficiency as a test-platform to evaluate FVII gene therapy in humans

Paris Margaritis

PDF Pages: S610-S612 Full Text (2755) Open Access

Long-term safety of targeted agents used to treat metastatic renal cell carcinoma: the issue is not the rate of adverse events over time, but the expertise needed to manage them

Camillo Porta, Silvia Chiellino

PDF Pages: S613-S615 Full Text (3035) COI Form Open Access

Disclosure:

This supplement was published without any sponsorship or funding.